Michael Hulko
Overview
Explore the profile of Michael Hulko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
542
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Malard B, Hulko M, Koch J, Speidel R, Pouchoulin D, Echeverri J, et al.
ASAIO J
. 2025 Feb;
PMID: 39907151
Inflammatory mediators play a major role in the development and progression of acute kidney injury (AKI). Continuous renal replacement therapy (CRRT) removes these mediators from the blood using AN69-M, AN69-ST,...
2.
Hulko M, Dietrich V, Koch I, Gekeler A, Gebert M, Beck W, et al.
Sci Rep
. 2019 May;
9(1):6791.
PMID: 31043670
Haemodialysis effectively removes small solutes and smaller-sized middle molecules from the blood; however, the clearance of larger middle molecules, which have been associated with negative effects, is poor. The novel...
3.
Voigt M, Gebert M, Haug U, Hulko M, Storr M, Boschetti-de-Fierro A, et al.
Sci Rep
. 2019 Apr;
9(1):6370.
PMID: 31015539
Middle molecules (MMs) are associated with the pathology of uraemia, and are not effectively removed by standard extracorporeal treatments. Increased convection used in haemodiafiltration (HDF) can enhance the removal of...
4.
Hulko M, Haug U, Gauss J, Boschetti-de-Fierro A, Beck W, Krause B
Artif Organs
. 2018 Oct;
42(12):1164-1173.
PMID: 30281162
Sieving coefficients reported in dialyzer data sheets and instructions for use (IFUs) indicate the potential of different solutes to pass across a particular membrane. Despite being measured in vitro, sieving...
5.
Schepers E, Glorieux G, Eloot S, Hulko M, Boschetti-de-Fierro A, Beck W, et al.
BMC Nephrol
. 2018 Jan;
19(1):1.
PMID: 29304774
Background: Membranes with increasing pore size are introduced to enhance removal of large uremic toxins with regular hemodialysis. These membranes might theoretically have higher permeability for bacterial degradation products. In...
6.
Trojanowicz B, Ulrich C, Fiedler R, Martus P, Storr M, Boehler T, et al.
Nephrol Dial Transplant
. 2017 Oct;
33(1):34-43.
PMID: 28992224
Background: High mortality of haemodialysis patients is associated with systemic chronic inflammation and overactivation of the renin-angiotensin system (RAS). Insufficient elimination of pro-inflammatory immune mediators, especially in the molecular weight...
7.
Hulko M, Speidel R, Gauss J, Storr M, Krause B
Int J Artif Organs
. 2017 Sep;
40(11):615-621.
PMID: 28862721
Purpose: Removal of cytokines is relevant for dialysis patients as they are suspected to promote cardiovascular complications. The objective of this study was to benchmark membranes with different permeability profiles...
8.
Latosinska A, Hulko M, Speidel R, Mischak H, Storr M, Krause B
Artif Organs
. 2017 Jul;
42(1):78-87.
PMID: 28744941
Despite multiple efforts to target an improvement in clinical outcomes of patients with end-stage renal disease, several challenges must still be addressed. Dialysis patients are at a high risk for...
9.
Zweigart C, Boschetti-de-Fierro A, Hulko M, Nilsson L, Beck W, Storr M, et al.
Int J Artif Organs
. 2017 Jun;
40(7):328-334.
PMID: 28574113
No abstract available.
10.
Willy K, Hulko M, Storr M, Speidel R, Gauss J, Schindler R, et al.
Artif Organs
. 2017 May;
41(9):803-809.
PMID: 28524237
Recently developed high-flux (HF) dialysis membranes with extended permeability provide better clearance of middle-sized molecules such as interleukins (ILs). Whether this modulation of inflammation influences the procalcific effects of septic...